Want to see HK:3737 full AI Analyst Report?
3737 Stock Chart & Stats
HK$0.88
HK$0.04(4.04%)
At close: 4:00 PM EST
HK$0.88
HK$0.04(4.04%)
Day’s Range― - ―
52-Week RangeHK$0.50 - HK$0.98
Previous CloseN/A
Volume157.00K
Average Volume (3M)401.89K
Market Cap
HK$622.54M
Enterprise ValueHK$588.70
Total Cash (Recent Filing)HK$185.38M
Total Debt (Recent Filing)HK$87.63M
Price to Earnings (P/E)30.3
Beta0.04
Next Earnings
Mar 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.8%
Share Statistics
EPS (TTM)0.02
Shares Outstanding863,600,000
10 Day Avg. Volume402,600
30 Day Avg. Volume401,893
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.38
Price to Sales (P/S)0.24
P/FCF Ratio5.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModest leverage relative to equity reduces financial risk and preserves flexibility for operations, investment, and shareholder returns. The stable equity base provides resilience over the next several quarters, although current profitability is not yet generating strong returns on that capital.
Positive Cash GenerationPositive operating cash flow and free cash flow show that the business can still convert operations into funding without relying entirely on external capital. That supports ongoing investment and financial resilience, even though the latest cash generation was weaker and remains volatile.
Healthy Gross ProfitabilityA gross margin near 54% indicates that Zhongzhi retains meaningful product-level profitability within its Chinese patent medicine and healthcare portfolio. This provides a foundation for recovering operating earnings if cost pressure eases, despite currently thin downstream margins.
Bears Say
Sharp Revenue DeclineThe sharp annual revenue contraction signals weaker demand, distribution, or product traction than in the prior year. Sustained top-line pressure would reduce operating leverage, limit reinvestment capacity, and make it harder for the company to rebuild earnings over the next several quarters.
Severe Margin CompressionThe steep decline in net and operating margins leaves a much thinner cushion against further cost pressure or revenue weakness. Even with healthy gross profitability, limited operating conversion makes earnings more vulnerable and reduces the durability of near-term profit generation.
Low Returns On EquityThe sharp ROE decline shows that the company’s substantial equity base is currently producing very little profit. Persistently weak capital efficiency could constrain internally generated growth, reduce the attractiveness of reinvestment, and signal that profitability recovery is not yet established.
Zhongzhi Pharmaceutical Holdings Limited News
3737 FAQ
What was Zhongzhi Pharmaceutical Holdings Limited’s price range in the past 12 months?
Zhongzhi Pharmaceutical Holdings Limited lowest stock price was HK$0.50 and its highest was HK$0.98 in the past 12 months.
What is Zhongzhi Pharmaceutical Holdings Limited’s market cap?
Zhongzhi Pharmaceutical Holdings Limited’s market cap is HK$622.54M.
When is Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date?
Zhongzhi Pharmaceutical Holdings Limited’s upcoming earnings report date is Mar 25, 2027 which is in 175 days.
How were Zhongzhi Pharmaceutical Holdings Limited’s earnings last quarter?
Zhongzhi Pharmaceutical Holdings Limited released its earnings results on Aug 26, 2026. The company reported HK$0.012 earnings per share for the quarter.
Is Zhongzhi Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Zhongzhi Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Zhongzhi Pharmaceutical Holdings Limited pay dividends?
Zhongzhi Pharmaceutical Holdings Limited pays a Annually dividend of HK$0.05 which represents an annual dividend yield of 6.8%. See more information on Zhongzhi Pharmaceutical Holdings Limited dividends here
What is Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate?
Zhongzhi Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhongzhi Pharmaceutical Holdings Limited have?
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding.
What happened to Zhongzhi Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Zhongzhi Pharmaceutical Holdings Limited reported an EPS of HK$0.012 in its last earnings report. Following the earnings report the stock price went down -3.623%.
Which hedge fund is a major shareholder of Zhongzhi Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:3737
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhongzhi Pharmaceutical Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.02%
12-Months-Change
Fundamentals
Return on Equity
6.80%
Trailing 12-Months
Asset Growth
0.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Pak Fah Yeow International Limited
―